Navigation Links
TechniScan Announces Adding Another Center to Worldwide Clinical Trials for New Breast Imaging System
Date:6/16/2010

SALT LAKE CITY, June 16 /PRNewswire-FirstCall/ -- TechniScan, (OTC Bulletin Board: TSNI) a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, today announced that it has launched a clinical study in Rochester, Minn., its third new clinical site to commence in the last five months.

TechniScan's Warm Bath Ultrasound (WBU) system is designed to capture three-dimensional images of the breast as a woman lies prone on a table and state-of-the-art ultrasound technology is used in a warm water tank to image the breast anatomy. Its revolutionary new method of imaging produces information and whole breast images that are not available with traditional reflection ultrasound or whole breast ultrasound systems presently on the market.

To date, TechniScan has scanned over 800 women in clinical studies in Salt Lake City and Ogden, Utah as well as Orange and San Diego, California. These past clinical studies focused on key factors like image quality, repeatability, and establishing protocols for testing baseline values for positive and negative predictive capabilities of the system.

According to Dr. John Klock, TechniScan's chief medical officer, the most recently completed clinical work continues to support that refraction-corrected reflection images highlight connective tissue features within the breast, whereas the speed-of-sound images show fibroglandular, ductal and terminal lobular units with high resolution.  

Image consistency and reproducibility, whether it is weeks, months or a year between exams, are critical to support precise and reliable assessment of breast lesions. Clinical studies in San Diego recently evaluated the ability of the system to reliably reproduce images from the same woman.

"We have clearly demonstrated that the system can reliably reproduce images based on reflection and sound transmission and that those images will have significant clinical utility," said David Robinson TechniScan's president and CEO.

"Volumetric whole-breast imaging provides a substantial practical advantage over conventional very-small-field-of-view sonography. We are greatly aided by the ability to produce repeatable whole-breast comparisons – left to right and present to past. These comparisons are the nuts and bolts of breast imaging, by any modality," said Michael Andre, Ph.D., adjunct professor of radiology and director of medical physics at University of California, San Diego School of Medicine.

Building on this prior clinical work, the current clinical studies in Freiberg, Germany, San Diego and Rochester will involve at least 500 women with various types of breast lesions.  Major objectives of the 12-month study will be to compare WBU to conventional breast sonography and MRI as well as to examine the WBU system's ability to differentiate between normal, benign and malignant breast tissue. These clinical studies in the U.S. are funded by a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute.

TechniScan's current study sites include the University Medical Center Freiburg in Germany, Moores UCSD Cancer Center, and the latest clinical study site in Rochester, Minnesota as well as limited imaging studies that support product development in Genoa, Italy and Salt Lake City, Utah.

"Overall we expect to image another 600 or more patients in our clinical program over the next 6-12 months," said Robinson. "These studies will provide us with critical information about the clinical utility and application of the WBU capabilities."

"The feedback that we are receiving from our scientists and radiologists at our study sites gives us good reasons to remain cautiously optimistic," said Klock.

Researchers involved in the studies will also utilize TechniScan's groundbreaking imaging network, which provides them with the ability to archive, store, and retrieve WBU images and relevant medical records and to collaborate with other research sites.  

"Our vision is to begin to create a database of thousands of breast images as well as the underlying and related image data," said Robinson. "With complete anonymity, women can contribute their mammograms, breast MRI's and WBU images along with related pathology and other information to provide researchers around the world an unprecedented opportunity to study breast cancer. TechniScan's imaging network will also allow timely and efficient collaboration of patient's records for her medical team's use. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system."

About TechniScan

TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. TechniScan's WBU imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit www.techniscanmedical.com.

Forward Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate, "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "Company") to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the Company's Annual Report on Form 10-K filed on March 22, 2010. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Press Contact: Tracy Harden, TechniScan Medical Systems, (801) 994-2968, tharden@tsni.com


'/>"/>
SOURCE TechniScan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patent Awarded to the Design of TechniScans Unique 3-D Breast Imaging System
2. TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg University
3. TechniScan Cofounder to Speak at SPIE Medical Imaging Conference About Ground-Breaking Science Behind the Companys Ultrasound Technology
4. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
5. Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging
6. Epocal Announces FDA Clearance of Lactate Test
7. Adeona Announces HartLab Expansion Into Microbiology Testing Services
8. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 6.83% during the period ... growth prospects of the global travel vaccines market for 2016-2020. To ... the sales of various vaccines administered to actively immunize meningococcal disease, ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West ... January 1, 2017. The name change aligns the entire company with its ... health care quality. , “We are very proud of the achievements associated with ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , ... and other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger ... vice president of sales. , Litsinger joined Mirixa in 2008 after serving ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
Breaking Medicine News(10 mins):